Test Price
2,800 AED✅ Home Collection Available
CERS3 Gene Sequencing for Autosomal Recessive Congenital Ichthyosis Type 9 (ARCI9) – UAE
Executive Summary & Core Metrics
This Next‑Generation Sequencing (NGS) test provides definitive mutation detection for CERS3‑linked Autosomal Recessive Congenital Ichthyosis Type 9. It is performed under the DHA facility license 1143 at DNA Labs UAE, Dubai Healthcare City, ensuring full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health data security.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM across the UAE.
- Clinical Guidance: Telephonic post‑test clinical guidance session with a certified genetic counsellor.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CERS3 gene sequencing test identifies disease‑causing mutations in the CERS3 gene responsible for autosomal recessive congenital ichthyosis type 9 (ARCI9), a severe skin barrier disorder. Using NGS with full bioinformatics confirmation, the assay delivers 99.9% analytical sensitivity for single‑nucleotide variants, small insertions/deletions, and copy‑number variants. Results are available within 3–4 weeks and include carrier screening and family risk assessment.
| Feature | Our Test (NGS) | Single‑Gene Sanger Sequencing |
|---|---|---|
| Precision | 99.9% analytical sensitivity for CERS3 variants | ~95% – misses large deletions/duplications |
| Methodology | NGS with full bioinformatics confirmation | Sanger sequencing of coding exons only |
| Turnaround Time | 3 – 4 weeks | 6 – 8 weeks |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I see families carrying the burden of a rare skin disorder without a clear diagnosis. This NGS test for ARCI9 offers a precise molecular answer, guiding management and enabling informed family planning. However, genetic results must always be interpreted within the full clinical context. Do not stop or alter any prescribed treatments without direct advice from your treating physician.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Clinical Advisory Prior to Testing
- If you are taking anticoagulant therapy, obtain clearance from your prescribing physician before blood collection.
- Any active infection (including skin infections) should be resolved before sample collection to avoid contamination.
- This test is for diagnostic confirmation of ARCI9; it does not replace ongoing clinical care or urgent medical consultation.
Safety Exclusions & Emergency Red Flags
- Exclusion Criteria: Individuals on anticoagulant therapy must obtain written physician clearance. Active skin infection at the intended blood‑draw site requires rescheduling until resolved.
- Emergency Red Flags: Sudden blistering, high fever, or signs of systemic infection demand immediate emergency care — do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. What does the CERS3 gene test diagnose?
This NGS test identifies mutations in the CERS3 gene to confirm a diagnosis of autosomal recessive congenital ichthyosis type 9 (ARCI9). It detects both known and novel variants, guiding dermatologists and pediatricians in personalized management and family planning.
2. How is the sample collected for this genetic test?
A standard peripheral whole blood sample (EDTA tube) can be collected. Alternatively, a FTA card dried blood spot or an already extracted DNA sample may be accepted. Our VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection is available daily from 8 AM to 11 PM across the UAE. You can also visit our DHA‑licensed laboratory in Dubai Healthcare City.
3. How long do results take and will a doctor explain them?
Results are ready in 3 to 4 weeks and include a telephonic post‑test clinical guidance session with a certified genetic counsellor. This ensures you fully understand the implications for treatment, surveillance, and family members.
UAE Regulatory & Data Privacy Adherence
Compliance & Data Security
This genetic test is performed in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- ISO 9001:2015 quality management certification (INT/EGQ/2509DA/3139)
Your sample and data are protected under strict confidentiality protocols. Results are accessible only to authorized healthcare professionals and the patient. The DHA facility license (No. 1143) guarantees regulatory oversight by the Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | CERS3 Gene Sequencing for Autosomal Recessive Congenital Ichthyosis Type 9 (ARCI9) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube), FTA card, or extracted DNA sample |
| Methodology Used | Next‑Generation Sequencing (NGS) with full bioinformatics confirmation |
| ICD‑10‑CM Code | Q80.8 |
| LOINC Code | 48018-6 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians